Ads
related to: recombinant activated protein c deficiency- Browse FAQs
Frequently answered questions.
Find answers here.
- RUO Recombinant Proteins
In stock and ready to ship.
Check out our offers.
- Animal-Free Proteins
Avoid animal-derived components.
Browse our proteins.
- GMP Grade Proteins
Anicillary materials.
Meets rigorous standards.
- Browse FAQs
Search results
Results From The WOW.Com Content Network
Protein C, also known as autoprothrombin IIA and blood coagulation factor XIV, [5]: 6822 [6] is a zymogen, that is, an inactive enzyme.The activated form plays an important role in regulating anticoagulation, inflammation, and cell death and maintaining the permeability of blood vessel walls in humans and other animals.
Protein C is vitamin K-dependent. Patients with Protein C deficiency are at an increased risk of developing skin necrosis while on warfarin. Protein C has a short half life (8 hour) compared with other vitamin K-dependent factors and therefore is rapidly depleted with warfarin initiation, resulting in a transient hypercoagulable state.
Protein C Anticoagulant Pathway: Thrombin escaping from a site of vascular injury binds to its receptor thrombomodulin (TM) on the intact cell surface. As a result, thrombin loses its procoagulant properties and instead becomes a potent activator of protein C. Activated protein C (APC) functions as a circulating anticoagulant, which ...
Deficiency in factor XI is known to cause hemophilia C. [9] Factor XIIa is another plasma protein that is involved in the activation of zymogen factor is activated into factor XIa. [10] This activation is important to the coagulation cascade.
The factor VIII protein has a half-life of 12 hours in the blood stream when stabilized by the von Willebrand factor. [20] No longer protected by vWF, activated FVIII is proteolytically inactivated in the process (most prominently by activated protein C and factor IXa) and quickly cleared from the blood stream.
The blood coagulation and Protein C pathway.. Factor IX is produced as a zymogen, an inactive precursor.It is processed to remove the signal peptide, glycosylated and then cleaved by factor XIa (of the contact pathway) or factor VIIa (of the tissue factor pathway) to produce a two-chain form, where the chains are linked by a disulfide bridge.